Document Type : Original Article
Department of Obstetrics and Gynecology, School of Medicine, Ayatollah Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
Department of Obstetrics and Gynecology, School of Medicine, Ayatollah Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran,
Department of Pediatrics, School of Medicine, Ayatollah Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran,
Background: The evidence for the effect of corticosteroid administration on neonates in pregnant women who tested positive for COVID-19 is rare. This study aims to evaluate the effect of the administration of corticosteroids on pregnant women with COVID-19 on neonatal metabolic outcomes of hypoglycemia and hyperbilirubinemia.
Methods: The present retrospective cohort study was conducted on pregnant women with COVID-19 referred to Mousavi Hospital in Zanjan, Iran in 2020. We compared post-delivery complications in women who had received corticosteroids with a control group. The data were extracted from the medical records of the patients by a resident of the gynecology. The chi-square test was used to compare the rate of hyperbilirubinemia and hypoglycemia between groups.
Results: Of a total of 71 investigated patients, only 32 received non-steroidal anti-inflammatory drugs (NSAIDs),. The mean age of the patients was 29.77±6.87 years and there was not a significant difference between the two groups in terms of age, BMI, education, blood sugar, bilirubin, neonate weight, and 1 and 5-minute Apgar score (P>0.05). In the corticosteroid-receiving group, a significantly higher rate of hypoglycemia (37.5% vs. 7.69%, P=0.002) and hyperbilirubinemia (25% vs. 5.13%, P=0.02) was reported.
Conclusion: The results suggested that the administration of corticosteroids as a treatment modality for pregnant women with COVID-19 is associated with an increased rate of neonatal hypoglycemia and hyperbilirubinemia. Therefore, glycemic control is necessary for neonates born from pregnant women with COVID-19 exposed to corticosteroids during the pregnancy.